Innerscope Hearing Technologies Inc (OTCMKTS: INND) On Watch as Hearing Aid Pioneer Launches Line of 4 OTC Hearing Aid Models to Retailers & Pharmacy Chains
Innerscope Hearing Technologies Inc (OTCMKTS: INND) is one of the most exciting stocks on the bulletin boards that has been heating up ever since the new FDA OTC Hearing Aid Law was enacted allowing hearing aids to be sold over the counter without a prescription. InnerScope has already launched a line of 4 OTC hearing aid models priced between $499.99 to $999.99 now being shipped out to the Company’s extensive distribution network of major retailers and pharmacy chains including Walmart Vision Centers, RiteAid.com, BestBuy.com, and Amazon.com just to name a few.The stock is coming back strong on Wednesday after a shake to a low of $0.0127.
InnerScope, along with its wholly-owned subsidiary HearingAssist has been a leader in the direct-to-consumer hearing space since 2008, with nearly 500,000 customers. As a result, InnerScope is confident that it is in a prime position for this new emerging OTC hearing aid market. Currently InnerScope’s CPA firm, Paris, Kreit & Chiu LLP is preparing the Company’s 2021 and year-to-date 2022 audited financial statements with the objective of InnerScope becoming a fully reporting public company and ultimately pursuing an up-list to the NASDAQ stock exchange.The Company’s CEO Matthew Moore made a presentation on Wednesday afternoon at the Emerging Growth Conference.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
InnerScope Hearing Technologies (OTC: INND)i s a manufacturer and distributor of OTC Hearing Aids, Hearing Aid Accessories & Hearing Health-Related Products (“Hearing Products”) dedicated to addressing the global demand for affordable hear ing solutions. InnerScope’s Hearing Products and its B2C and B2B business model break through the persistent barriers that prevent access to effective and affordable hearing solutions.
InnerScope’s recent acquisition of iHEAR Medical Inc., a Direct-to-Consumer (“DTC”) cloud-based hearing solution provider, gives the Company access to over 40 patents and an R&D facility. In addition, InnerScope has acquired HearingAssist, an established leader since 2008 in the DTC hearing aid market with a customer base of over 400,000. These acquisitions, combined with a partnership with Atlazo Inc., a semiconductor innovator for next-generation AI smart devices, will allow InnerScope to better position itself in the OTC hearing aid market by selling advanced Hearing Products through Walmart and many other major retailers and pharmacy chains.
InnerScope’s full line of Hearing Products is currently available through these multiple retail/wholesale distribution channels: Walmart Vision Centers, Walmart.com, Walmart Canada, RiteAid.com, BestBuy.com, Amazon.com, Fingerhut.com, Giant Eagle, Hy-Vee, Hartig Drug, Food City, Cardinal Health™ at-Home, FSAStore.com, HSAStore.com, and WellDeservedHealth.com. More in-store and online Hearing Products will soon launch with more major retailers and pharmacy chains.
— InnerScope Hearing Technologies (OTC: $INND) (@inndstock) October 21, 2022
InnerScope launched its hearIQ App in 172 countries in the Apple App Store for iOS devices and Google Play Store for Android devices. The hearIQ App is a multi-functional app, which offers to the general public a FREE Self-Administered Hearing Test to determine hearing loss (if any) and also provides a Bluetooth wireless connection (“App Controlled”) for InnerScope’s Direct-to-Consumer Self-Fitting-Self-Adjusting Hearing Aids. The hearIQ App is specifically designed to help with early detection of hearing loss for the 48+ million Americans as well as the 1.5 billion people worldwide who may have an undetected hearing loss or may be living with some degree of hearing loss, according to the World Health Organization (“WHO”). More importantly, if hearing loss is detected, the hearIQ App directly links to InnerScope’s Direct-to-Consumer Hearing Products. Since the hearIQ App became activated only nine days ago, it has already received over 440 reviews and has a FIVE-STAR RATING from Apple and Android users.
INND operates in the booming hearing aids space; According to a report from Fortune Business Insights the global hearing aids market is set to gain impetus from the increasing adoption of telehealth among audiologists to prevent patient traffic. The report further states that the market size was USD 8.99 billion in 2019 and is projected to reach USD 13.38 billion by 2027, exhibiting a CAGR of 8.2% during the forecast period.
Recently the Company reported record Q2 revenues of $6,910,386 compared to $404,676 for first-quarter ended March 31, 2022. As a result, InnerScope recorded a $3,881,620 net profit for the three months ended June 30, 2022, and a Positive EBT of 56% for Q2 2022. Total consolidated net revenues were $7,315,062 for six months ended June 30, 2022, compared to $47,392 for six months ended June 30, 2021. The consolidated net revenues (based on the GAAP revenue booked in Q2 2022) represent approximately a 1,707% increase for Q2 2022 versus Q1 2022 and a 15,435% increase versus the same period ended June 30, 2021. In addition, based on purchase orders over $4,000,000 that have already been filled and delivered, which will be recognized as revenue for the third quarter of 2022, InnerScope projects continued record-setting revenues for the remaining six months of 2022 and beyond from the anticipated monthly replenishment purchase orders as well as new purchase orders from numerous retailers.
In October InnerScope launched its new line of affordable Over-the-Counter (OTC) rechargeable hearing aids for its iHEAR brand which includes app-controlled models with full wireless audio streaming of music and hands-free phone calling (“iHEAR OTC Hearing Aids”). The launch of iHEAR OTC Hearing Aids coincides with the Food and Drug Administration (“FDA”) finalizing the rule that started on October 17, 2022, which allows OTC hearing aids to be sold online and in major retail stores and pharmacy chains without a prescription or a need to see a medical or hearing professional from the Over-the-Counter Hearing Aid Act of 2017.
InnerScope, along with its wholly-owned subsidiary HearingAssist has been a leader in the direct-to-consumer hearing space since 2008, with nearly 500,000 customers. As a result, InnerScope is confident that it is in a prime position for this new emerging OTC hearing aid market, beginning with the launch of iHEAR OTC Hearing Aids and its well-established wholesale distribution network of major retailers and pharmacy chains. iHEAR OTC Hearing Aid Rechargeable Models are:
InnerScope initially launched iHEAR OTC Hearing Aids with two model types and four levels of technology. The model types and levels of technology are for the individual to choose based on their lifestyle and current or desired listening environments. Prices range from $499.99 to $999.99. InnerScope has begun shipping the iHEAR OTC Hearing Aids to its wholesale distribution network of major retailers and pharmacy chains. InnerScope has developed a quick and easy online guide for consumers to select the proper iHEAR OTC Hearing Aids and technology level. To find out which iHEAR OTC Hearing Aid is right for you, please visit: https://innd.outgrow.us/innd-97
InnerScope CEO Matthew Moore stated: “We designed these models and technology features in iHEAR’s new OTC Hearing Aids for all different or desired lifestyles and individual hearing needs. For example, the Premium Technology is for someone often in challenging listening environments, i.e., parties, large gatherings, and sporting events. The Advance Technology is for more moderate listening environments, i.e., restaurants, attending meetings, or religious services. The Essential Technology is for low-noise environments, i.e., family conversations around the dinner table. Our team of R&D engineers and our technology partners worldwide are continuing to develop new next-generation OTC hearing aids with voice-activated AI smart technology for the 48+ million Americans who are reported to have untreated hearing loss but could never afford the high cost of traditional prescription hearing aids.”
Currently trading at a $110 million market valuation INND OS is 7,461,001,280 shares with 5,329,706,040 shares in the float. Management is working hard behind the scenes, looking to uplist the Company Nasdaq as well as working with counsel to cancel minimum 216 million shares and up to 721 million shares from Crown Bridge, they are also looking to lower the authorized and recently eliminated $3.4 million in debt leaving zero convertible debt besides from the acquisition. As we have been saying INND is among the most exciting stocks in small caps that has enormous upside potential. Currently INND Hearing Assist centers are being rolled out at Walmart nationwide. The recently enacted FDA OTC Hearing Aid Law allows consumers to purchase OTC Hearing Aids right off the shelf directly from multiple retailers, including Big Box retailers and pharmacy chains. Over the past few years InnerScope has been diligently working to put into place a network of multiple large retailers, including Walmart, Best Buy, Rite Aid with wholesale vendor agreements to sell its assortment of hearing aid products and related hearing aid supplies ahead of the OTC Hearing Aid Law being enacted. InnerScope has already launched a line of 4 OTC hearing aid models priced between $499.99 to $999.99 now being shipped out to the Company’s extensive distribution network.INND has a large and fast growing shareholder base that swears this one goes way higher. INND ran to highs of just under $0.10 in early 2021.We will be updating on INND when more details emerge so make sure you are subscribed to Microcapdaily.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in INND either long or short and we have not been compensated for this article
Reunion Neuroscience (NASDAQ: REUN) shares jump 119% as they announce an exciting new development. The clinical-stage biopharmaceutical company has entered into a take-private transaction with MPM BioImpact, representing a significant milestone for Reunion Neuroscience. The transaction is valued at $13.1 million, a 43.1% premium to Reunion’s common shares’ 30-day volume-weighted average price.
Going private is a significant step for Reunion Neuroscience, as it means that a sizeable private-equity group or consortium of private-equity firms will purchase or acquire the stock of the publicly traded corporation.
To Discover the Inside Scoop on REUN, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Under the terms of the Arrangement Agreement, all holders of outstanding common shares of Reunion will be entitled to receive $1.12 in cash for each share held immediately before the effective time of the Arrangement. However, the agreement’s closing is subject to several conditions, which must be met before the transaction can be completed.
— JC Capital Consultants (@CapitalJc) June 1, 2023
Hostile takeover?
While management and the board think it is a significant milestone achieved, others think differently – an investor rights law firm, Halper Sadeh LLC, is currently investigating it… The sale of Reunion Neuroscience to affiliates of MPM BioImpact for $1.12 per share in cash is currently being investigated by Halper Sadeh LLC.
The investigation concerns whether Reunion and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Reunion shareholders; (2) determine whether MPM is underpaying for Reunion; and (3) disclose all material information necessary for Reunion shareholders to assess and value the merger consideration adequately. On behalf of Reunion shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
$Reun Reunion Neuro we are buying this little Gem up. Could see this at $3 in coming months. Great acquisition $13 ,million just for starters . Watch this space 💎
Reunion Neuroscience’s stock performance has been relatively volatile in recent years. The stock’s median target price, according to analysts’ forecasts, is $5.00, but there is a wide range of estimates, with a high of $20.00 and a low of $0.73. The current consensus among polled investment analysts is to buy $REUN stock. However, they’re a pre-revenue clinical-stage biopharmaceutical company, which means the last earnings reported a loss in the current quarter’s earnings per share – they’ve yet to generate any significant revenue. Until recently, shareholders experienced a significant decline in the stock’s value this year and were down ~54% prior to the acquisition. There are ~9M shares in the float, with ~28% and ~13% held by insiders and institutional investors, respectively.
Solid scalp for a quick win on $REUN. Low float but not really that much volume so it appears to be done and tanking accordingly. Time for this old dog to go into town.
Overall, investors should carefully consider the potential risks and rewards associated with investing in Reunion Neuroscience, considering the wide range of price estimates and the company’s current financial performance. Thorough research and the advice of a financial professional are recommended before making any investment decisions.
We will update you on REUN when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Marker Therapeutics, Inc. (Nasdaq: MRKR) shares surged by 45% as the company released positive pre-clinical Data on one of its candidates, MT-601. They tested it on lymphoma cells in the lab, and the results showed that MT-601 can kill lymphoma cells resistant to another treatment called CD19 CAR T therapy, which is fascinating news considering many patients who receive CD19 CAR T therapy still experience a relapse within a year.
“We have recently developed a long-term in vitro model to monitor the interaction of T cells with cancerous cells. Data from a lymphoma cell line utilizing this model demonstrated that MT-601 inhibited the growth of lymphoma cells as well as the growth of CD19 CAR-resistant lymphoma cells,” said Eric A. Smith, Ph.D., Director of Research and Development at Marker Therapeutics. Marker has posted further details about this preclinical study on the Investor Relations section of its website.
$MRKR Marker Therapeutics reveals positive pre-clinical results of its MT-601 MultiTAA-Specific T Cell Product Candidate in lymphoma cells.
Dr. Smith continued, “Specifically, we have developed an in vitro model which reproduces the CD19 antigen-negative tumor that causes relapse and observed the following:
To Discover the Inside Scoop on MRKR, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
In this in vitro model, 98% of lymphoma cells were eliminated after a CD19-targeting CAR T cell product was administered.
— DayRanger – Investors Underground (@DayRanger) May 31, 2023
While the CAR T cells significantly controlled lymphoma cell growth, we observed that three weeks after the start of anti-CD19 CAR T cell administration, a population of lymphoma cells resistant to CD19 CAR T cell administration started to grow.
These CD19 CAR-resistant lymphoma cells were tested for CD19 expression. They were shown to be negative for the CD19 surface antigen, which explained why they were no longer controlled with a second administration of anti-C19 CAR T cells, thus recapitulating the antigen-negative relapse observations in CAR relapsed/refractory lymphoma patients.
However, when MT-601, with its broad antigen recognition (Survivin, NY-ESO-1, WT-1, PRAME, MAGE-A4, SSX2), was added to this anti-CD19 CAR T cell resistant cell population, complete growth inhibition was observed.
These data highlight that MT-601 can potentially eliminate CD19 CAR T cell refractory tumors, indicating that MT-601 might offer a viable therapeutic option for lymphoma patients that have relapsed from previous CAR T cell interventions.”
MT-601 targets multiple substances on cancer cells and may provide longer-lasting results than CD19 CAR T therapy. Marker Therapeutics has started a clinical trial to test MT-601 on lymphoma patients who have relapsed after CD19 CAR T therapy or cannot receive it. The early lab results showed that MT-601 could inhibit the growth of lymphoma cells, including those resistant to CD19 CAR T therapy. The initial results have shown remarkable promise, and the team is thrilled to advance the testing of MT-601 in further clinical trials to evaluate its effectiveness and safety.
About Marker Therapeutics, Inc.
Marker Therapeutics is a company currently in the advanced stages of clinical research for developing innovative treatments in immuno-oncology. Their primary focus is on creating next-generation immunotherapies that utilize T cells, a type of immune cell, to target and fight against hematological malignancies (cancers of the blood, such as leukemia and lymphoma) and solid tumors (cancers that form in tissues or organs). These therapies aim to harness the immune system’s power to specifically recognize and eliminate cancer cells, offering potential new treatment options for patients with these types of cancers.
Marker Therapeutics has an outstanding total of 8.8M shares and presents a relatively small float of 6.64M shares available for public trading. Insiders hold approximately 12.82% of the shares, while institutional investors hold around 22.63%. Examining their trading history, the average volume typically hovers around 100,000 shares. In light of the positive news today, the trading activity trended much higher, with an impressive 27M shares traded at time of writing. This translates to a 270-fold increase compared to their average volume, also 4x their float.
— Nick Sullivan Life & Medicare Agency (@SprouttSales) May 31, 2023
It is essential to recognize the high volatility and rapid movements associated with Marker Therapeutics’ stock, primarily driven by the limited availability of shares. Such stocks tend to attract the interest of day and swing traders, given their propensity for swift gains or losses based on trading strategies. As evidence, a single positive news catalyst in the biotech sector can trigger a substantial surge in stock price and exponentially increase trading volume to unprecedented levels.
We will update you on MRKR when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic. The London Clinic is UK’s most renowned independent, private hospital, established 1932 with their Spine Clinic being the first specialist spinal unit based in England back in 1997.
“With a focus on providing the very best healthcare outcomes, The London Clinic is an ideal customer for Aclarion as the company works to deliver the Nociscan solution to physicians and patients around the world,” said John Sutcliffe MD, Neurosurgeon and Founder of London Spine Clinic. “The engagement with Aclarion will allow London Spine Clinic to continue offering the high-quality care our patients have come to expect. Patients need a careful assessment, diagnosis, and understanding of the different treatment options. Aclarion’s innovative Nociscan solution will enable us to objectively assess biomarkers associated with low back pain and enhance the precision of each diagnosis.”
$ACON Aclarion Announces New Engagement with The London Clinic and London Spine Clinic
Aclarion, Inc.’s Nociscan Technology is an innovative medical solution that aims to revolutionize the diagnosis of disc-related conditions. They leverage biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain.
$ACON Watching for volume and run. Aclarion Announces New Engagement with The London Clinic and London Spine Clinic
What’s exciting is its advantages over the current standard of care. It offers a non-invasive approach, ensuring patient comfort and safety. Given it’s non-invasive, that also means 0 pain with 0 radiation (typically associated with traditional discography). The best part is it can seamlessly integrate into standard lumbar MRI protocols, making it a convenient and efficient option for healthcare providers.
To Discover the Inside Scoop on ACON, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
The procedure takes approximately 25-45 minutes, thoroughly evaluating spinal discs without compromising accuracy. Additionally, Nociscan technology offers significant cost savings, with a list price of $1,450, making it an affordable alternative to traditional discograms. Overall, Aclarion, Inc.’s technological advances represent a significant push forward in disc-related diagnostic techniques, prioritizing patient well-being, convenience, and affordability.
They also recently completed a study that spanned two years and involved 78 patients at a single site. The success rate soared to an impressive 85% for patients whose treatment strategy aligned with the disks identified by Nociscan. This represented a remarkable 22% improvement over patients whose treatment strategy did not consider the insights provided by Nociscan.
Aclarion expressed confidence that the results of the trial demonstrate the potential of Nociscan to assist physicians in successfully treating DLBP. Dr. Matthew Gornet, orthopedic surgeon and lead author of the study, enthusiastically endorsed Nociscan, stating, “The two-year surgical outcomes of the clinical trial provide unequivocal evidence of its effectiveness, particularly with regards to the primary endpoint, the Oswestry Disability Index (ODI). I firmly believe that Nociscan has the potential to revolutionize the standard of care and accurately aid all physicians treating chronic low back pain.”
$ACON Watching for volume and run. Aclarion Announces New Engagement with The London Clinic and London Spine Clinic
It is worth noting that although Nociscan was performed on all patients in the study, it was not part of the surgical decision-making process, as highlighted by the company.
The commercial agreement between Aclarion, Inc. and the prestigious London Clinic signifies a significant milestone for both parties, carrying the potential for global recognition, revenue growth, and scalability. By integrating Aclarion’s innovative Nociscan Technology, the London Clinic demonstrates its commitment to delivering cutting-edge healthcare to optimize patient well-being and enhance clinical outcomes. Furthermore, the partnership’s success holds the potential for scaling Nociscan Technology to other institutions and markets, propelling Aclarion, Inc. to become a global leader in non-invasive medical technologies while driving substantial revenue growth.
We will update you on ACON when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.